(Q39677403)
Statements
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing (English)
Oliver Gautschi
Konstantin Dedes
Joachim Diebold
Mario Pietrini
Roger von Moos
Swiss Group for Clinical Cancer Research